Dabigatran etexilate
- Generic Name
- Dabigatran etexilate
- Brand Names
- Pradaxa
- Drug Type
- Small Molecule
- Chemical Formula
- C34H41N7O5
- CAS Number
- 211915-06-9
- Unique Ingredient Identifier
- 2E18WX195X
- Background
Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monit...
- Indication
Dabigatran etexilate is available in both oral pellet and capsule form. Dabigatran etexilate pellets are indicated for the treatment of venous thromboembolic events (VTE) in pediatric patients between three months and 12 years of age who have been treated with a parenteral anticoagulant for at least 5 days. They are also indicated in the same age group to re...
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Venous Thromboembolism
- Associated Therapies
- -
A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT02568397
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma
- Conditions
- Interventions
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2018-07-13
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 15
- Registration Number
- NCT02426229
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Johannes Gutenberg University Mainz
- Target Recruit Count
- 64
- Registration Number
- NCT02256683
- Locations
- 🇩🇪
Universitätsmedizin Leipzig, Leipzig, Germany
🇩🇪Charité Universitätsmedizin Berlin, Berlin, Germany
🇩🇪University Heart Center; Department of Cardiology and Angiology II, Bad Krozingen, Germany
Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)
- Conditions
- Interventions
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1506
- Registration Number
- NCT02240667
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5390
- Registration Number
- NCT02239120
- Locations
- 🇩🇪
Klinikum Coburg gGmbH, Coburg, Germany
🇩🇪Klinikzentrum Mitte, Dortmund, Dortmund, Germany
🇩🇪Klinikum Hanau GmbH, Hanau, Germany
Safety of Dabigatran Etexilate in Blood Clot Prevention in Children
- Conditions
- Interventions
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 214
- Registration Number
- NCT02197416
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇨🇦Kingston General Hospital, Kingston, Ontario, Canada
🇱🇹Children Intensive Care Hosp,Anaesthesiology Dept,Vilnius, Vilnius, Lithuania
Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy Volunteers
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02173717
Relative Bioavailability of Dabigatran and Diclofenac After Dabigatran Etexilate and Diclofenac Single Dose Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02171507
Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42
- Registration Number
- NCT02171624
Bioavailability of Dabigatran With or Without Clarithromycin in Healthy Volunteers
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02171585
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.